Activation of CD8+ cytotoxic T lymphocyte

Activation of CD8+ cytotoxic T lymphocyte" refers to the process by which naive CD8+ T cells, upon recognizing antigen presented by MHC class I molecules on antigen-presenting cells and receiving necessary costimulatory and cytokine signals, differentiate into effector cytotoxic T lymphocytes. Once activated, these CTLs proliferate and acquire the ability to kill infected, cancerous, or otherwise abnormal cells by releasing cytotoxic granules (such as perforin and granzymes) or by engaging death receptors (e.g., Fas-FasL interaction), and secrete cytokines like IFN-γ and TNF-α to orchestrate the immune response. The activation process is tightly regulated by transcriptional, metabolic, and signaling networks and plays a critical role in antiviral, antitumor, and immune homeostasis.

Other names

CD8+ T cell activationCytotoxic T cell activationCTL activationCD8+ cytotoxic T lymphocyte activation

Not applicable to "activation" itself, but drugs that modulate CD8+ T cell activation act by: Blocking inhibitory pathways (immune checkpoints, e.g., PD-1/PD-L1 or CTLA-4 blockade); Providing or mimicking costimulatory signals (e.g., agonists for CD28, 4-1BB); Supplying inflammatory cytokines (e.g., IL-2, IL-12 supplementation); Enhancing antigen presentation or TCR engagement.